Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: A comparison with uterine endometrial adenocarcinoma

Oncology

Volumn 71, Issue 5-6, 2007, Pages 333-340

  Akahira, Jun Ichi ^a   Tokunaga, Hideki ^a   Toyoshima, Masafumi ^a   Takano, Tadao ^a   Nagase, Satoru ^a   Yoshinaga, Kosuke ^a   Tase, Toru ^c   Wada, Yuichi ^b   Ito, Kiyoshi ^a   Niikura, Hitoshi ^a   Yamada, Hidekazu ^d   Sato, Akira ^d   Sasano, Hironobu ^a   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SENDAI CITY MEDICAL CENTER   (Japan)

^c Miyagi Cancer Center   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Carcinosarcoma; Endometrial cancer; Monoclonal; Prognostic factors; Uterine sarcoma

Indexed keywords

CARBOPLATIN; DOXORUBICIN; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOSARCOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; JAPAN; LEIOMYOSARCOMA; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RISK FACTOR; SALPINGOOOPHORECTOMY; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; UNIVARIATE ANALYSIS; UTERUS SARCOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; JAPAN; LEIOMYOSARCOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SARCOMA, ENDOMETRIAL STROMAL; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 35348872771     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107107     Document Type: Article

References (58)

1. Harlow BL, Weiss NS, Lofton S: The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986;76:399-402.
2. Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, Gates EJ, Di Maio T, Marzec T: Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 1997;65:158-163.
3. Pautier P, Genestie C, Rey A, Morice P, Roche B, Lhomme C, Haie-Meder C, Duvillard P: Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000;88:1425-1431.
4. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, Gzerwenka K, Leodolter S, Kainz C: Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999;74:196-201.
5. Schwartz Z, Dgani R, Lancet M, Kessler I: Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol 1985;20:354-363.
6. Bazzocchi F, Brandi G, Pileri S, Mancuso A, Massaro A, Martinelli G: Clinical and pathologic prognostic features of leiomyosarcoma of the uterus. Tumori 1983;69:75-77.
7. Nola M, Babic D, Ilic J, Marusic M, Uzarevic B, Petrovecki M, Sabioncello A, Kovac D, Jukic S: Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 1996;78:2543-2550.
8. Kahanpaa KV, Wahlstrom T, Grohn P, Heinonnen E, Nieminen U, Widholm O: Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 1986;67:417-424.
9. Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Trope CG: The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 1996;62:254-259.
10. Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Trope CG: The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 1990;29:185-192.
11. Hendrickson MR, Kempson RL: Surgical Pathology of the Uterine Corpus. Philadelphia, Saunders, 1980.
12. McCluggage WG: Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2005;55:321-325.
13. Costa MJ, Vogels A, Young LTJ: P53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. Mod Pathol 1994;7:619-627.
14. Sreenan JJ, Hart WR: Carcinosarcoma of the female genital tract: a pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995;19:666-674.
15. Costa MJ, Walls J: Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors): clinicopathologic study of 82 cases. Cancer 1996;77:533-542.
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
17. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
18. Cox DR: Regression models and life tables. J R Stat Soc 1972;30:248-275.
19. Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E, Mayerhofer S, Czerwenka K, Leodolter S, Kainz C, Mayerhofer K: Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 2001;81:160-165.
20. Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, Yamashiro K, Kanemoto T, Kudo R: Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004;67:33-39.
21. Bodner-Adler B, Bodner K, Obermair A, Czerwenka K, Petru E, Leodolter S, Mayerhofer K: Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res 2001;21:3069-3084.
22. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, Conner W: Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33.
23. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A: Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005;23:3668-3675.
24. Yaegashi N, Ito K, Niikura H: Lymphadenectomy for endometrial cancer: is paraaortic lymphadenectomy necessary? Int J Clin Oncol;12:176-180.
25. Wick MR and Swanson PE: Carcinosarcomas: current perspectives and an historical review of nosological concepts. Semin Diagn Pathol 1993;10:118-127.
26. Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Brinton LA: Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998;69:253-257.
27. Schwartz SM, Weiss NS, Daling JR, Gammon MD, Liff JM, Watt J, Lynch CF, Newcomb PA, Armstrong BK, Thompson WD: Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer 1996;77:717-724.
28. McCluggage WG: Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-690.
29. Norris HJ, Roth E, Taylor HB: Mesenchymal tumors of the uterus. II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 1966;28:57-63.
30. Doss LL, Llorens AS, Henriquez EM: Carcinosarcoma of the uterus: a 40-year experience from the state of Missouri. Gynecol Oncol 1984;18:43-53.
31. George E, Manivel JC, Dehner LP, Wick MR: Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 1991;22:215-223.
32. Bitterman P, Chun B, Kurman RJ: The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. Am J Surg Pathol 1990;14:317-328.
33. Costa MJ, Khan R, Judd R: Carcinosarcoma [malignant mixed mullerian (mesodermal) tumor] of the uterus and ovary: correlation of clinical, pathologic and immunohistochemical features in 29 cases. Arch Pathol Lab Med 1991;115:583-590.
34. de Brito PA, Silverberg SG, Orenstein JM: Carcinosarcomas [malignant mixed mullerian (mesodermal) tumors] of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 1993;24:132-142.
35. Geisinger KR, Dobbs DJ, Marshall RB: Malignant mixed mullerian tumors: an ultrastructural and immunohistochemical analysis with histogenetic consideration. Cancer 1987;59:1781-1790.
36. Meis JM, Lawrence WD: The immunohistochemical profile of malignant mixed mullerian tumor: overlap with endometrial adenocarcinoma. Am J Clin Pathol 1990;94:1-7.
37. Mayall F, Rutty K, Campbell F, Goddard H: p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 1994;24:211-214.
38. Szukala SA, Marks JR, Burchette JL, Elbendary AA, Krigman HR: Coexpression of p53 by epithelial and stromal elements in carcinosarcoma or the female genital tract: an immunohistochemical study of 19 cases. Int J Gynecol Cancer 1999;9:131-136.
39. Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57:5379-5385.
40. Thompson L, Chang B, Barsky SH: Monoclonal origins of malignant mixed tumors (carcinosarcomas): evidence for a divergent histogenesis. Am J Surg Pathol 1996;20:277-285.
41. Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T: Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000;60:114-120.
42. Emoto M, Iwasaki H, Kikuchi M , Ishiguro M, Kubota T, Izumi H, Shirakawa K, Kaneko Y: Two cell lines established from mixed mullerian tumors of the uterus: morphologic, immunocytochemical and cytogenetic analysis. Cancer 1992;69:1759-1768.
43. Gorai I, Doi C, Minaguchi H: Establishment and characterisation of carcinosarcoma cell lines of the human uterus. Cancer 1993;71:775-786.
44. Emoto M, Iwasaki H, Kikuchi M, Shirakawa K: Characteristics of cloned cells of mixed mullerian tumor of the human uterus. Cancer 1993;71:3065-3075.
45. Yuan Y, Kim WH, Han HS, Lee JH, Park HS, Chung JK, Kang SB, Park JG: Establishment and characterization of cell lines derived from uterine malignant mixed mullerian tumor. Gynecol Oncol 1997;66:464-474.
46. Gorai I, Yanagibashi T, Taki, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Nagashima Y, Minaguchi H: Uterine carcinosarcoma is derived from a single stem cell: an in situ study. Int J Cancer 1997;72:821-827.
47. Ishiwata I, Ono I, Ishiwata C: Heterotransplantation of mixed mesodermal tumor cells in nude mouse - histology of metastatic foci. Gynecol Oncol 1998;27:189-196.
48. Rubin A: The histogenesis of carcinosarcoma (mixed mesodermal tumor) of the uterus as revealed by tissue culture studies. Am J Obstet Gynecol 1959;77:269-274.
49. Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, Van Robaeys J, Neven P, Moerman P, Vergote I: Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005;98:274-280.
50. George E, Lillemoe TJ, Twiggs LB, Perrone T: Malignant mixed mullerian tumor versus high grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44.
51. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RJ: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-632.
52. Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ: Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989;161:309-312.
53. Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962-1966.
54. Curtin JP, Blessing Jam Soper JT, DeGeest K: Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2001;83:268-270.
55. Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC: Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98:217-221.
56. Van Rijswijk REN, Vermorken JB, Reed N, Favalli G, Mendiola C, Zanaboni F, Mangili G, Vergote I, Guastalla MP, ten Bokkel Huinink WW, Lacave AJ, Bonnefoi H, Tumulo S, Rietbroek R, TeodorovicI, Coens C, Pecorelli S: Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract: a phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC55923). Eur J Cancer 2003;39:481-487.
57. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR: Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:526-531.
58. Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, Tase T: Clinical experience of combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 2004;94:774-778.